- Guselkumab is associated with clinical efficacy and good tolerability for patients with moderate to severe plaque psoriasis, according to a systematic review and meta-analysis of 7 randomized controlled trials (RCTs).
Why this matters
- This meta-analysis represents a comprehensive analysis of guselkumab to provide a basis for clinical application.
- Guselkumab was associated with superior efficacy compared with placebo (ORs; 95% CIs):
- ≥75 improvement in Psoriasis Area and Severity Index (PASI-75): 61.37 (31.15-120.91).
- Investigator’s Global Assessment score of 0 or 1 (IGA 0/1): 65.75 (45.54-94.95).
- Dermatology Life Quality Index score of 0 or 1 (DLQI 0/1): 29.64 (18.80-46.73).
- Guselkumab also was associated with superior efficacy compared with adalimumab (ORs; 95% CIs):
- PASI-75: 3.08 (2.35-4.06).
- IGA 0/1: 2.79 (2.17-3.59).
- DLQI 0/1: 1.86 (1.50-2.31).
- Guselkumab was associated with a similar incidence of adverse events and infections compared with placebo and adalimumab.
- Meta-analysis of 7 RCTs, including 1206 patients with plaque psoriasis treated with guselkumab, 1250 treated with adalimumab, and 585 who received placebo.
- Funding: None disclosed.
- No long-term safety analysis.